ПЕРИПРОЦЕДУРНОЕ ПОВРЕЖДЕНИЕ МИОКАРДА
https://doi.org/10.15829/1728-8800-2013-1-95-101
Аннотация
Реваскуляризация миокарда методом чрескожных коронарных вмешательств (ЧКВ) широко и эффективно используется для лечения ишемической болезни сердца с достижением немедленного успеха >90%. В зависимости от критериев диагностики, от 5% до 30% этих пациентов могут иметь признаки перипроцедурного повреждения миокарда (ППМ) или инфаркта миокарда (ПИМ). Предикторы развития ППМ, механизмы его появления и особенности клинической картины имеют важное значение в предупреждении ППМ. В определении и диагностике перипроцедурного некроза миокарда и ПИМ и их влияния на исходы до настоящего времени нет единой точки зрения. Согласно новейшим исследованиям, анализируемым в этом обзоре, в связи с высокой чувствительностью современных пороговых значений тропонина, возникло предложение о пересмотре современных критериев ППМ.
Об авторе
С. А. Акинина
Учреждение Ханты-Мансийского автономного округа — Югры, «Окружная клиническая больница», Ханты-Мансийск
Россия
Россия
заместитель главного врача по терапии
Тел./факс: (3467) 39–01–67, 8 (902) 819-93-79
Список литературы
1. Cavallini C, Savonitto S, Violini R, et al. Impact of the elevation of biochemical markers of myocardial damage on long-term mortality after percutaneous coronary intervention: results of the CK-MB and PCI study. Eur Heart J 2005; 26: 1494–8.
2. Califf RM, Abdelmeguid AE, Kuntz RE, et al. Myonecrosis after revascularization procedures. JACC 1998; 31: 241–51.
3. Herrmann J. Peri-procedural myocardial injury: 2005 update. Eur Heart J 2005; 26: 2493–519.
4. Porto I, Selvanayagam JB, Van Gaal WJ, et al. Plaque volume and occurrence and location of periprocedural myocardial necrosis after percutaneous coronary intervention: insights from delayed- enhancement magnetic resonance imaging, Thrombolysis in Myocardial Infarction myocardial perfusion grade analysis, and intravascular ultrasound. Circulation 2006; 114: 662–9.
5. Prasad A, Herrmann J. Myocardial infarction due to percutaneous coronary intervention. N Engl J Med 2011; 364: 433–64.
6. Bhatt DL, Topol EJ. Does creatinine kinase-MB elevation after percutaneous coronary intervention predict outcomes in 2005? Periprocedural cardiac enzyme elevation predicts adverse outcomes. Circulation 2005; 112: 906–15.
7. Cutlip DE, Kuntz RE. Does creatinine kinase-MB elevation after percutaneous coronary intervention predict outcomes in 2005? Cardiac enzyme elevation after successful percutaneous coronary intervention is not an independent predictor of adverse outcomes. Circulation 2005; 112: 916–22.
8. Prasad A, Rihal CS, Lennon RJ, et al. Significance of periprocedural myonecrosis on outcomes after percutaneous coronary intervention: an analysis of preintervention and post- intervention troponin T levels in 5487 patients. Circ Cardiovasc Interv 2008; 1: 10–9.
9. Ricciardi M, Wu E, Davidson C, et al. Visualization of discrete microinfarction after percutaneous coronary interventions associated with mild creatine kinase-MB elevation. Circulation 2001; 103: 2780–3.
10. Selvanayagam JB, Petersen SE, Francis JM, et al. Effects of off-pump versus on-pump coronary surgery on reversible and irreversible myocardial injury: a randomized trial using cardiovascular magnetic resonance imaging and biochemical markers. Circulation 2004; 109: 345–50.
11. Selvanayagam JB, Porto I, Channon K, et al. Troponin elevation after percutaneous coronary intervention directly represents the extent of irreversible myocardial injury: insights from cardiovascular magnetic resonance imaging. Circulation 2005; 111: 1027–32.
12. Jaffe AS. Biochemical detection of acute myocardial infarction. In: Gersh B, Rahimtoola S, eds. Acute Myocardial Infarction. New York, NY: Elsevier 1991; 110–27.
13. Saenger AK, Jaffe AS. Requiem for a Heavyweight. The Demise of Creatine Kinase-MB. Circulation 2008; 118: 2200–6.
14. Mair J, Artner-Dworzak E, Dienstl A, et al. Early detection of acute myocardial infarction by measurement of mass concentration of creatine kinase-MB. Am J Cardiol 1991; 68: 1545–50.
15. Collinson P, Rosalki S, Kuwana T, et al. Early diagnosis of acute myocardial infarction by CK-MB mass measurements. Ann Clin Biochem 1992; 29: 43–7.
16. Bakker A, Gorgels J, van Vlies B, et al. The mass concentrations of serum troponin T and creatine kinase-MB are elevated before creatine kinase and creatine kinase-MB activities in acute myocardial infarction. Eur J Clin Chem Clin Biochem 1993; 31: 715–24.
17. Adams JE, Bodor GS, Davila-Roman VG, et al. Cardiac troponin I: a marker with high specificity for cardiac injury. Circulation 1993; 88: 101–6.
18. Katus HA, Remppis A, Neumann FJ, et al. Diagnostic efficiency of troponin T measurements in acute myocardial infarction. Circulation 1991; 83: 902–12.
19. Adams JE, Schechtman KB, Landt Y, et al. Comparable detection of acute myocardial infarction by creatine kinase MB isoenzyme and cardiac troponin I. Clin Chem 1994; 40: 1291–5.
20. Apple FS, Falahati A, Paulsen PR, et al. Improved detection of minor ischemic myocardial injury with measurement of serum cardiac troponin I. Clin Chem 1997; 43: 2047–51.
21. Tanaka H, Abe S, Yamashita T, et al. Serum levels of cardiac troponin I and troponin T in estimating myocardial infarct size soon after reperfusion. Coron Artery Dis 1997; 8: 433–9.
22. Alpert J, Thygesen K, Antman E, et al. Myocardial Infarction Redefined — a consensus document of The Joint European Society of Cardiology/ American College of Cardiology Committe. JACC 2000; 36: 959–69.
23. Grines CL, Dixon S. A nail in the coffin of troponin measurements after percutaneous coronary intervention. JACC 2011; 57: 662–3.
24. Thygesen K, Alpert JS, White HD, on behalf of Joint European Society of Cardiology/American College of Cardiology/American Heart Association/ World Heart Federation Task Force for the Redefinition of Myocardial Infarction. Universal definition of myocardial infarction. Circulation 2007; 22: 2634–53.
25. 2009 Focused Updates: ACC/AHA Guidelines for the Management of patients with ST — elevation Myocardial Infarction (Updating the 2004 Guideline and 2007 Focused Update) and ACC/AHA/SCAI Guidelines on Percutaneous Coronary Intervention (Updating the 2005 Guideline and 2007 Focused Update). JACC 2009; 54: 2205–41.
26. Detre K, Holubkov R, Cowley M, et al. Percutaneous transluminal coronary angioplasty in 1985–1986 and 1977–1981. The National Heart, Lung, and Blood Institute Registry. N Engl J Med 1988; 318: 265–70.
27. Johansen O, Brekke M, Stromme J, et al. Myocardial damage during percutaneous transluminal coronary angioplasty as avidenced by troponin T measurements. Eur Heart J 1998; 19: 112–7.
28. Remppis A, Ehlermann P, Giannitsis E, et al. Cardiac troponin T levels at 96 hours reflect myocardial infarct size: a pathoanatomical study. Cardiology 2000; 93: 249–53.
29. Ricciardi MJ, Wu E, Davidson CJ, et al. Visualization of discrete microinfarction after percutaneous coronary intervention associated with mild creatine kinase-MB elevation. Circulation 2001; 103: 2780–3.
30. Natarajan MK, Kreatsoulas C, Velianou JL, et al. Incidence, predictors, and clinical significance of troponin-I elevation without creatine kinase elevation following percutaneous coronary interventions. Am J Cardiol 2004; 93: 750–3.
31. Gruberg L, Dangas G, Metran R, et al. Clinical outcome following percutaneous coronary interventions in patients with chronic renal failure. Catheter Cardiovasc Interv 2002; 55: 66–72.
32. McKechnie RC, Smith D, Montoye C, et al. Prognostic implication of anemia on in-hospital outcomes after percutaneous coronary intervention. Circulation 2004; 110: 271–7.
33. Kini A, Marmur JD, Kini S, et al. Creatine kinase-MB elevation after coronary intervention correlates with diffuse atherosclerosis, and low-tomedium level elevation has a benign clinical course: implications for early discharge after coronary intervention. JAСC 1999; 34: 663–71.
34. Fujii K, Carlier SG, Mintz GS, et al. Creatine kinase-MB enzyme elevation and long-term clinical events after successful coronary stenting in lesions with ruptured plaque. Am J Cardiol 2005; 95: 355–9.
35. Motmani JC, Topol EJ. Aortocoronary saphenous vein graft disease: pathogenesis, predisposition, and prevention. Circulation 1998; 97: 916–31.
36. Ashby DT, Dangas G, Aymong EA, et al. Effect of percutaneous coronary interventions for in-stent restenosis in degenerated saphenous vein grafts without distal embolic protection. JAСC 2003; 41: 749–52.
37. Wolfram R, Ledorgne L, Cheneau E, et al. Comparison of creatine kinase elevation and outcome of percutaneous coronary interventions for saphenous vein grafts in-stent restenosis versus de novo stenosis. Am J Cardiol 2003; 92: 980–3.
38. Mandadi VR, DeVoe MC, Ambrose JA, et al. Predictors of troponin elevation after percutaneous coronary intervention. Am J Cardiol 2004; 93: 747–50.
39. Ledorgne L, Cheneau E, Pichard A, et al. Effect of direct stenting on clinical outcome in patients treated with percutaneous coronary interventions on saphenous vein grafts. A Heart J 2003; 146: 501–6.
40. Ballarino MA, Moreyra EJr, Damonte A, et. al. Multicenter randomized comparison of direct vs. conventional stenting the DIRECTO trial. Catheter Cardiovasс Interv 2003; 58: 434–40.
41. Prasad A, Gersh BJ, Bertrand ME, et al. Prognostic significance of periproce- dural versus spontaneously occurring myocardial infarction after percutaneous coronary intervention in patients with acute coronary syndromes: an analysis from the ACUITY (Acute Catheterization and Urgent Intervention Triage Strategy) trial. JACC 2009; 54: 477–86.
42. Hong YJ, Mintz GS, Kim SW, et al. Impact of plaque composition on cardiac troponin elevation after percutaneous coronary intervention: an ultrasound analysis. JACC Cardiovasc Imaging 2009; 2: 458–68.
43. Uetani T, Amano T, Ando H, et al. The correlation between lipid volume in the target lesion, measured by integrated backscatter intravascular ultrasound, and post-procedural myocardial infarction in patients with elective stent implantation. Eur Heart J 2008; 29: 1714–20.
44. Bahrmann P, Werner GS, Heusch G, et al. Detection of coronary microembolization by Doppler ultrasound in patients with stable angina pectoris undergoing elective percutaneous coronary interventions. Circulation 2007; 115: 600–8.
45. Kini AS, Lee P, Duffy ME, et al. Postprocedure chest pain after coronary stenting: implications on clinical restenosis. JACC 2003; 33–8.
46. Robbins MA, Marso SP, Wolski K, et al. Сhest pain — strong predictor of adverse cardiac events following percutaneous intervention (from the Evalution of Platelet IIb/IIIa inhibitor for Stenting Trial (EPISTENT). Am J Cardiol 1999; 84: 1350–3.
47. Stone GW, Mehran R, Dangas G, et al. Differential impact on survival of electrocar- diographic Q-wave versus enzymatic myocardial infarction after percutaneous intervention: a device-specific analysis of 7147 patients. Circulation 2001; 104: 642–7.
48. Ellis SG, Chew D, Chan A, et al. Death following creatine kinase-MB elevation after coronary intervention: identification of an early risk period: importance of cre- atine kinase-MB level, completeness of revascularization, ventricular function, and probable benefit of statin therapy. Circulation 2002; 106: 1205–10.
49. Kugelmass AD, Cohen DJ, Moscucci M, et al. Elevation of the creatine kinase myocardial isoform following otherwise successful directional coronary atherectomy and stenting. Am J Cardiol 1994; 74: 748–54.
50. Abdelmeguid AE, Topol EJ, Whitlow PL, et al. Significance of mild transient release of creatine kinase- MB fraction after percutaneous coronary interventions. Circulation 1996; 94: 1528–36.
51. Kong TQ, Davidson CJ, Meyers SN, et al. Prognostic implication of creatine kinase elevation following elective coronary artery interventions. JAMA 1997; 277: 461–6.
52. Saucedo JF, Mehran R, Dangas G, et al. Long-term clinical events following creatine kinase-myocardial band isoenzyme elevation after successful coronary stenting. JACC 2000; 35: 1134–41.
53. Jeremias A, Baim DS, Ho KK, et al. Differential mortality risk of postprocedural creatine kinase-MB elevation following successful versus unsuccessful stent procedures. JACC 2004; 44: 1210–4.
54. Topol EJ, Mark DB, Lincoff AM, et al. Outcomes at 1 year and economic implications of platelet glycoprotein IIb/IIIa blocade in patients undergoing coronary stenting: results from a multicentre randomized trial. EPISTENT Investigators. Lancet 1999; 354: 2019–24.
55. Lincoff AM, Tcheng JE, Califf RM, et al. Sustained suppression of ischemic complications of coronary intervention by GP IIb/IIIa blocade with abciximab: one-year outcome in EPILOG trial. Evaluatoin in PTCA to improve long-term outcome with abciximab GP IIb/IIIa blocade. Circulation 1999; 99: 1951–8.
56. Topol EJ, Ferguson JJ, Weisman HF, et al. Long-term protection from myocardial ischemic events in a randomized trial of brief integrin beta3 blocade with percutaneous coronary intervention. EPIC Investigator Group. Evaluation of platelet IIb/IIIa inhibition for prevention of ischemic complication. JAMA 1997; 278: 479–84.
57. Nienhuis MB, Ottervanger JP, Bilo HJG, et al. Prognostic value of troponin after elective percutaneous coronary intervention: a meta-analysis. Cath Cardiovasc Intervent 2008; 71: 318–24.
58. Kizer JR, Muttrej MR, Matthai WH, et al. Role of cardiac troponin T in the long-term risk stratification of patients undergoing percutaneous coronary intervention. Eur Heart J 2003; 24: 1314–22.
59. Nienhuis MB, Ottervanger JP, Bilo HJ, et al. Prognostic value of troponin after elective percutaneous coronary intervention: a meta-analysis. Catheter Cardiovasc Interv 2008; 71: 318–24.
60. Testa L, Van Gaal WJ, Biondi Zoccai GG, et al. Myocardial infarction after percutaneous coronary intervention: a meta-analysis of troponin elevation applying the new universal definition. QJM 2009; 102: 369–78.
61. Prasad A, Singh M, Lerman A, Lennon RJ, et al. Isolated elevation in troponin T after percutaneous coronary intervention is associated with higher long-term mortality. JACC 2006; 48: 1765–70.
62. Nallamothu BK, Chetcuti S, Mukher-jee D, et al. Prognostic implication of troponin I elevation after percutaneous coronary intervention. Am J Cardiol 2003; 91: 1272–4.
63. Feldman DN, Minutello RM, Bergman G, et al. Relation of troponin I levels following nonemergent percutaneous coronary intervention to short- and long-term outcomes. Am J Cardiol 2009; 104: 1210–5.
64. Cantor WJ, Newby LK, Christenson RH, et al. Prognostic significance of elevated troponin I after percutaneous coronary intervention. JACC 2002; 39: 1738–44.
65. Kini AS, Lee P, Marmur JD, et al. Correlation of postpercutaneous coronary intervention creatine kinase-MB and tro- ponin I elevation in predicting mid-term mortality. Am J Cardiol 2004; 93: 18–23.
66. De Labriolle A, Lemesle G, Bonello L, et al. Prognostic significance of small tro- ponin I rise after a successful elective percutaneous coronary intervention of a native artery. Am J Cardiol 2009; 103: 639–45.
67. Cavallini C, Verdecchia P, Savonitto S, et al. Prognostic value of elevation after percutaneous coronary intervention. Circ Сardiovasc Interv 2010; 3: 431–5.
68. Jeremias A, Kleiman NS, Nassif D, et al. Prevalence and prognostic significance of preprocedural cardiac troponin elevation among patients with stable coronary artery disease undergoing percutaneous coronary intervention: results from the Evaluation of Drug Eluting Stents and Ischemic Events registry. Circulation 2008; 118: 632–8.
69. Hamm CW, Ravkilde J, Gerhardt W, et al. The prognostic value of serum troponin T in unstable angina. N Engl J Med 1992; 327: 146–50.
70. Lim CCS, van Gaal WJ, Testa L, et al. With the ‘universal definition,’ measurement of creatine kinase-myocardial band rather than troponin allows more accurate diagnosis of periprocedural necrosis and infarction after coronary intervention. JACC 2011; 57: 653–61.
71. Bhatt DL, Lincoff AM, Gibson CM, et al. Intravenous platelet blockade with cangrelor during PCI. N Engl J Med 2009; 361: 2330–41.
72. Cutlip DE, Windecker S, Mehran R, et al. Clinical end points in coronary stent trials: a case for standardized definitions. Circulation 2007; 115: 2344–51.
73. Vranckx P, Cutlip DE, Mehran R, et al. Myocardial infarction adjudication in contemporary all-comer stent trials: balancing sensitivity and specificity. Eur Intervention 2010; 5: 4.
Рецензия
Для цитирования:
Акинина С.А. ПЕРИПРОЦЕДУРНОЕ ПОВРЕЖДЕНИЕ МИОКАРДА. Кардиоваскулярная терапия и профилактика. 2013;12(1):95-101. https://doi.org/10.15829/1728-8800-2013-1-95-101
For citation:
Akinina S.A. PERIPROCEDURAL MYOCARDIAL DAMAGE. Cardiovascular Therapy and Prevention. 2013;12(1):95-101. (In Russ.) https://doi.org/10.15829/1728-8800-2013-1-95-101
Просмотров: 1621
Послать статью по эл. почте 
